Invasive Lobular Carcinoma: A Harder to Detect Breast Cancer

Triple-Negative Breast Cancer (TNBC) — The Aggressive Type “When Breast Cancer Lacks Three Key Receptors — It’s Called Triple-Negative.” 💬 Triple-Negative Breast Cancer (TNBC) is an aggressive subtype that tests negative for estrogen, progesterone, and HER2 receptors — the three key markers often targeted in treatment. Because it doesn’t respond to hormonal or HER2-targeted therapy, TNBC needs strong support for both treatment tolerance and recovery. 🧬 Key Facts: Accounts for 10–15% of all breast cancers Grows and spreads faster than other types More common in younger women (under 50) ⚠️ Symptoms: Rapidly enlarging lump Pain, swelling, or redness Lymph node enlargement Mechanism / Usage: Mamosure, a scientifically proven, result-based phyto-therapeutic product, supports: Cellular repair and immune modulation Maintenance of oxidative balance Improved recovery and tissue resilience during therapy 🌿 Mamosure – Scientific Phyto-Therapeutic for Breast Cancer Care & Prevention www.mamosure.com | #Mamosure #TNBC #BreastCancerAwareness #ScientificHealing #PhytoTherapeutics

Breast cancer screenings are meant to bring clarity, not confusion. For women with dense breast tissue, mammograms can sometimes leave more questions than answers. At Astrin, we’re pioneering a new approach — using deep proteomics and AI to detect early signs of cancer through a simple blood test, designed to bring greater accuracy and confidence to every screening experience. Our CEO, Jayant Parthasarathy, and Chief Medical Officer, Dr. Badrinath Konety, share this vision in their new piece for STAT. Read it here ⬇️ : https://lnkd.in/eE4KUtJE

Excited to see Astrin Biosciences vision for earlier, more accessible breast cancer detection featured in STAT — and co-authored by our CEO, Jayant Parthasarathy, and Chief Medical Officer, Dr. Badrinath Konety. Every day, our team is pushing the boundaries of what’s possible in blood-based diagnostics to give women clarity and confidence in their screening journey. Looking forward to what’s ahead, and to the future of early detection!

As clinicians and scientists, we know early detection saves lives. In this article published in @STAT Jayant Parthasarathy Parthasarathy and I discuss how Astrin Biosciences is harnessing proteomics and AI to develop a blood-based test that could make early breast cancer detection simpler, faster, and more accessible for all women. Proud to be part of this mission.

Innovation in early cancer detection is transforming healthcare. Our client, Astrin Biosciences, is leading this shift with a new approach designed to detect breast cancer earlier — particularly in women with dense breast tissue. In this STAT piece, Astrin’s CEO, Jayant Parthasarathy and Chief Medical Officer, Dr. Badrinath Konety, discuss how deep proteomics and AI are paving the way for more accurate, accessible screening. Read more here: https://lnkd.in/eE4KUtJE

🎗️ Breast Cancer Awareness Month: Biomarkers Driving the Next Frontier This October, let’s spotlight where the science is moving. 🔬 Breakthroughs in Triple-Negative Breast Cancer (TNBC) A Phase 3 trial (TROPION-Breast02) shows that the new drug Dato-DXd significantly improves survival versus chemotherapy in immunotherapy-ineligible metastatic triple-negative breast cancers (TNBC), a major step forward for this hard-to-treat group. 🔗 https://lnkd.in/gd-TQnZT And in another trial, early analyses suggest that in TNBCs, being ctDNA-negative before surgery is linked to excellent outcomes regardless of pathologic complete response (pCR) status, indicating ctDNA may be a stronger long-term outcome biomarker than pCR. 🔗 https://lnkd.in/g5pTP85t This matters for health equity: Black women experience higher TNBC incidence and worse outcomes, reflecting both biological and systemic factors and some inherited mutations (BRCA1/2, BARD1, PALB2, RAD51C/D) raise risk further. 💡 Why this matters Biomarkers now guide care, escalating when necessary, sparing when safe. And new studies show ctDNA can track recurrence risk in real time, even when scans appear clear. 🔮 Look for new updates to URMA as we add graphical prompt commands that optimizes our model for breast cancer trial matching. We're so excited! #BreastCancerAwareness #TNBC #Biomarkers #PrecisionMedicine #TargetedTherapy #CancerResearch #HealthEquity

🌎 Real-World Capecitabine in Latin America: Not a “one-size-fits-all” Solution for Residual TNBC Population: 360 women with non-metastatic TNBC and residual disease after neoadjuvant chemo; 106 (≈29%) received adjuvant capecitabine. Overall cohort: capecitabine did not improve OS (HR 0.79; p=0.30) or DFS (HR 0.81; p=0.32) in the matched analysis. Subgroup signals: substantial benefit in high residual burden (pT3–pT4) and in patients who did not receive radiotherapy. (OS HR ~0.29; DFS HR ~0.37) 💡 My reflections & clinical takeaway: This isn’t practice up-ended, but refined. These results tell me: Capecitabine remains valuable for TNBC patients with extensive residual disease post-NACT. Its benefit may be compromised if radiotherapy is also given — suggesting interplay between locoregional therapy and systemic intensification. For those with lower residual burden, routine adjuvant capecitabine may offer limited added value — risks, tolerability, patient preference should guide decisions. We need large, prospective trials in non-Asian populations to confirm which subgroups truly gain. Until then, personalize: map residual disease burden, consider radiotherapy status, and ensure patients know both potential benefits & limits. 🔗 Breast Cancer Res Treat. 2025: “Survival impact of adjuvant capecitabine in triple-negative breast cancer Latin American patients with residual disease: a real-world study” https://lnkd.in/eJmYfCPx #TNBC #AdjuvantTherapy #Capecitabine #ResidualDisease #RealWorldEvidence #BreastCancer #OncologyInsights

#HerBreastCareInsights - Post 136 Rethinking Breast Cancer: The Hidden Burden of Invasive Lobular Carcinoma (ILC) Breast cancer is the most common cancer among women. Among its subtypes, triple-negative breast cancer (TNBC) and invasive ductal carcinoma (IDC) are well recognized. In contrast, invasive lobular carcinoma (ILC) remains a uniquely challenging subtype to detect clinically due to its distinct biological and morphological features. *New national data from the NCI and CDC highlight essential trends: ·      In 2021, ILC incidence was 14 per 100,000 women, accounting for 10.6% of all breast cancer diagnoses. ·      Rates increased from 2012–2021 across all racial and ethnic groups — from +2.5% annually in American Indian/Alaska Native women to +4.4% annually in Asian American/Pacific Islander women. ·      White women had the highest overall incidence (14.7/100k), followed by Black women (11/100k). Among women under 50, American Indian/Alaska Native women had the second-highest rates. ·      Survival: ILC outcomes are slightly higher than ductal carcinoma for the first 7 years post-diagnosis but decline for regional and distant-stage disease — likely reflecting its unique metastatic pattern. Why this matters ILC’s distinct biology can delay detection, limit treatment response, and worsen outcomes for advanced disease. Recognizing ILC as a separate entity in research and clinical trials is essential to: ✅ Identify unique risk factors ✅ Optimize treatment strategies ✅ Advance understanding of metastatic behavior ✅ Improve outcomes for the growing number of women affected *For details and complete results, read: Angela N. Giaquinto et al., Lobular breast cancer statistics, 2025, V131(20), 15 October 2025, e70061

“Prevention is better than cure.” In breast cancer, early detection truly can be the cure. Two recent publications underscore just how critical it is to catch breast cancer early, and how powerful screening programs can be when widely adopted. 1. In The BMJ cohort study, nearly 32.1 % of women invited to their first mammography screening did not participate. Over 25 years of follow-up: * Non-participants had a 40 % higher risk of death from breast cancer (9.9 vs 7.0 deaths per 1,000 women) * Non-participants were more likely to receive diagnoses at advanced stages: odds ratio 1.53 for stage III, 3.61 for stage IV vs those who did attend. * The incidence of breast cancer was similar between groups, which suggests that the excess mortality is largely driven by delayed detection, not a higher incidence. This shows that missing that first screening isn’t just a missed appointment but may translate into a long-term survival disadvantage. 2. In Frontiers in Public Health, the authors examine the psychosocial and behavioral determinants influencing women’s screening decisions. Key findings: * In Poland, breast cancer incidence has surged by 60 % over 20 years, and mortality by 30 %. * Despite this rising burden, only 31 % of eligible women underwent mammography in 2024—well below the 70–80 % threshold often posited as necessary for population-level benefit. * Among other determinants, women were significantly more likely to participate if they had prior education about breast cancer, higher health-behavior scores, certain psychosocial attitudes, and emotional support. Combined, these studies send a powerful message: even in contexts where screening is available, uptake, education, psychological factors, and access barriers all influence who benefits. At SurgMark (www.surgmark.com), we believe in doing more than simply making products. We are committed to being part of the solution—to help bridge gaps in early detection and follow-through. Our metal-free breast tissue markers are designed to support clinicians in diagnosis, surgical precision, and longitudinal care, especially in settings where accuracy and safety matter. We stand firm in our mission: to support the global fight against breast cancer with innovation, quality, and purpose. References: 1. https://lnkd.in/eQ9D6uiW 2. https://lnkd.in/ex5WzKuu Dr. Peter A. Meier, MBA Dr. Christine Koenig Thomas Freier Dr. Rivelino Montenegro Frank Drs. med. Schure Frank und Viola Karl Luschmann #breastcancer #surgmark #cancerprevention

Understanding the Different Types of Blood Cancer Blood cancer, also called hematologic cancer, affects the blood, bone marrow, or lymphatic system, interfering with the body’s ability to produce healthy blood cells. Early awareness and detection can make a significant difference in treatment outcomes. Types of Blood Cancer: Leukemia: Begins in the bone marrow, causing abnormal white blood cells to multiply. Common types include ALL, CLL, AML, and CML. Symptoms: fatigue, frequent infections, bruising, and weight loss. Lymphoma: Starts in the lymphatic system, affecting lymphocytes. Includes Hodgkin and Non-Hodgkin lymphoma. Symptoms: swollen lymph nodes, fever, night sweats, and unexplained weight loss. Multiple Myeloma: Impacts plasma cells, weakening bones and immunity. Symptoms: bone pain, recurrent infections, anemia, and kidney issues. Myelodysplastic Syndromes (MDS) & Myeloproliferative Neoplasms (MPN): Involve abnormal production of blood cells in the bone marrow, causing fatigue, bleeding, and organ enlargement. Treatment & Care: Blood cancer treatment depends on type and stage and may involve chemotherapy, targeted therapy, immunotherapy, radiation, or bone marrow/stem cell transplant. HCG Cancer Centre offers cutting-edge technology, compassionate care, and expert medical teams to provide effective treatment for all types of blood cancer. #HCGCCK #EmotionalResilience #HopeAndHealing #EarlyDetection #Bloodcancer #CancerPrevention #HealthMatters #MensHealth #BloodCancerAwarenessMonth